ARCHIVES

Study: Routine CT Not Needed In Detecting DLBCL Remissions

This article is from The Cancer Letter archive.

Vol. 36 No. 5 | May 31, 2013

Download PDF Visit The Full Archive

Related Articles

Phase II Elotuzumab Study Demonstrates 33 Months PFS

July 26, 2013

1.7% Cut Expected in NCI Budget Under Deficit Agreement

November 24, 1989

FDA Approves Velcade For Treatment Of Refractory Multiple Myeloma

May 30, 2003

President’s FY 1987 Budget Trims NCI 473 Million From 1986 Appropriation; Basic Research Hit Hard

February 7, 1986

Literature Review Supports Need for More Research In Cancer Control

July 19, 1985

Obey Raps Reagan Administration For Blocking Report On Formaldehyde Danger

March 27, 1981